Ablynx wins award for 'Most successful early phase trial"

26-Oct-2009 - Belgium

Ablynx announced it has been awarded "Most Successful Early Phase Trial" at the 2009 Good Clinical Practice Journal‟s (GCPj) Clinical Research Excellence Awards in London. The GCPj's Awards recognise excellence in clinical research and development.

Commenting on the award, Chief Medical Officer Josi Holz said: “It is a great honour to receive this prestigious award. We are pleased that our lead programme, a novel anti-thrombotic, ALX-0081 entered a Phase II study in patients undergoing percutaneous coronary intervention (PCI) last month. The award recognises our innovative Phase I clinical trial design and the acceleration of this programme through the use of biomarkers and PK/PD modelling to establish biological effective dosing in patients. We have achieved the rapid progress with ALX-0081 thanks to a dedicated Ablynx team and our collaborators at the OLVZ in Aalst and PRA International.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances